Provided by Tiger Fintech (Singapore) Pte. Ltd.

X4 Pharmaceuticals Inc

0.3401
+0.02357.42%
Post-market: 0.3399-0.0002-0.06%19:19 EDT
Volume:1.48M
Turnover:499.54K
Market Cap:58.00M
PE:-3.96
High:0.3498
Open:0.3268
Low:0.3200
Close:0.3166
Loading ...

Company Profile

Company Name:
X4 Pharmaceuticals Inc
Exchange:
NASDAQ
Establishment Date:
- -
Employees:
143
Office Location:
61 North Beacon Street,4th Floor,Boston,Massachusetts,United States
Zip Code:
02134
Fax:
- -
Introduction:
X4 Pharmaceuticals, Inc., a late-stage clinical biopharmaceutical company, focuses on the research, development, and commercialization of novel therapeutics for the treatment of rare diseases. Its lead product candidate is mavorixafor, a small molecule inhibitor of the chemokine receptor C-X-C chemokine receptor type 4 (CXCR4), which is in Phase III clinical trial for the treatment of patients with warts, hypogammaglobulinemia, infections, and myelokathexis syndrome; and Phase Ib clinical trial to treat chronic neutropenia and Waldenström macroglobulinemia. The company is also developing X4P-002, a CXCR4 antagonist for the treatment of brain cancers; and X4P-003, a CXCR4 antagonist for the treatment of CXCR4 disorders and primary immunodeficiencies. It has a license agreement with Abbisko Therapeutics Co., Ltd. to develop, manufacture, and commercialize mavorixafor in combination with checkpoint inhibitors or other agents in oncology indications. The company is headquartered in Boston, Massachusetts.

Directors

Name
Position
Michael S. Wyzga
Chairman of the Board of Director
Paula Ragan
President, Chief Executive Officer, Secretary and Director
David McGirr
Director
Gary J. Bridger
Director
Isaac Blech
Director
Murray W. Stewart
Director
Rene Russo
Director

Shareholders

Name
Position
Paula Ragan
President, Chief Executive Officer, Secretary and Director
Adam S. Mostafa
Chief Financial Officer and Treasurer
E. Lynne Kelley
Chief Medical Officer